Glucagen Hypokit (Glucagon)

Glucagen Hypokit is indicated for the emergency treatment of severe hypoglycemia when rapid glucose elevation is required.

• Adults and children with insulin‑induced hypoglycemia who cannot safely consume oral carbohydrates.
• Situations where blood glucose is < 50 mg/dL (2.8 mmol/L) and the patient is symptomatic.
• Use during diabetic emergencies in hospital, outpatient, or home settings when immediate correction is needed.
• Administration by trained healthcare professionals or caregivers following a hypoglycemia protocol.
• As a rescue medication for patients on insulin pump therapy experiencing pump failure.

The safety profile of Glucagen Hypokit reflects the pharmacologic actions of glucagon and the route of injection.

Common

• Nausea or vomiting, typically occurring shortly after injection.
• Flushing, warmth, or mild erythema at the injection site.
• Headache that resolves within a few hours.
• Transient increase in blood pressure or heart rate.

Serious

• Severe allergic reaction (anaphylaxis) presenting with difficulty breathing, swelling, or hives.
• Hypersensitivity skin reactions such as rash, itching, or angio‑edema.
• Cardiac arrhythmia or chest pain in patients with pre‑existing heart conditions.

When using Glucagen Hypokit, clinicians should observe several precautions to ensure safe and effective treatment.

• Verify hypoglycemia with a blood glucose measurement before administration, unless the patient is unconscious.
• Use only the prescribed dosage and avoid repeat dosing without medical supervision.
• Monitor the patient’s vital signs and glucose level after injection.
• Exercise caution in patients with pheochromocytoma, adrenal insufficiency, or known glucagon hypersensitivity.
• Avoid use in individuals with severe cardiovascular disease unless benefits outweigh risks.
• Store the kit at controlled room temperature and protect from light.
• Discard any solution that appears discolored or contains particles.

Glucagen Hypokit may interact with certain medications or clinical conditions, influencing its efficacy or safety.

Avoid

• Beta‑blockers, which may mask typical glucagon‑induced tachycardia and affect glucose response.
• Insulin secretagogues (e.g., sulfonylureas) that can precipitate recurrent hypoglycemia after glucagon administration.
• Monoamine oxidase inhibitors (MAOIs) that may potentiate cardiovascular effects.

Use with caution

• Anticholinergic agents, as they may blunt the glycogenolytic response.
• Calcium channel blockers, which could affect hemodynamic stability.
• Patients receiving catecholamines or other vasoactive drugs; monitor blood pressure closely.